# Post-marketing Surveillance for Hypertensive Patients With Diabetes and/or Chronic Kidney Disease

> **NCT01363336** · — · COMPLETED · sponsor: **Bayer** · enrollment: 1882 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Nifedipine (Adalat CR, BAYA1040)

## Key facts

- **NCT ID:** NCT01363336
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2013-06
- **Final completion:** 2013-07
- **Target enrollment:** 1882 (ACTUAL)
- **Last updated:** 2015-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01363336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01363336, "Post-marketing Surveillance for Hypertensive Patients With Diabetes and/or Chronic Kidney Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01363336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*